Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis

Netanel A. Horowitz*, Israel Henig, Oryan Henig, Noam Benyamini, Liat Vidal, Irit Avivi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Data regarding clinical characteristics, therapy, maternal and fetal outcomes of pregnancy-associated acute myeloid leukemia (PA-AML) are limited. This study (including 138 cases published between 1955 and 2013) provides comprehensive assessment of these clinical parameters and may serve as a platform for developing management recommendations. Most patients (58%) received anthracycline–cytarabine-based regimens (ACBRs), which were associated with significantly increased complete remission (CR: 91%). Yet, the maternal overall survival (OS: ∼30%) was relatively low, probably reflecting reduced application of risk-adapted consolidation and allogeneic stem cell transplantation (allo-SCT). Fetal exposure to ACBRs resulted in a live birth rate of 87%, with complications (16%) diagnosed only in chemotherapy-subjected neonates. This study demonstrates safety and efficacy of ACBRs during pregnancy. Therapy and delivery schedule should allow early referral of high-risk patients to allo-SCT. Generation of a pool of high-quality data on PA-AML could contribute to providing evidence-based therapy and lead to improved maternal and fetal survival.

Original languageEnglish
Pages (from-to)610-616
Number of pages7
JournalLeukemia and Lymphoma
Issue number3
StatePublished - 4 Mar 2018


  • Acute myeloid leukemia
  • anthracycline-based regimens
  • pregnancy


Dive into the research topics of 'Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this